Inactive Instrument

Allena Pharmaceuticals, Inc.

Equities

ALNA

US0181191075

Biotechnology & Medical Research

Allena Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020

March 09, 2021 at 07:00 am EST

Allena Pharmaceuticals, Inc. announced earnings results for the fourth quarter ended December 31, 2020. For the fourth quarter, the company announced net loss was USD 10.258 million compared to USD 11.359 million a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.47 a year ago. For the full year, net loss was USD 32.845 million compared to USD 47.339 million a year ago. Basic loss per share from continuing operations was USD 1.01 compared to USD 2.13 a year ago.

Latest news about Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Went Out of Business	23-06-20	CI
First Amended Liquidation Plan Approved for Allena Pharmaceuticals, Inc.	23-05-18	CI
First Amended Liquidation Plan Filed by Allena Pharmaceuticals, Inc.	23-05-15	CI
Interim Combined Hearing for Disclosure Statement and Plan Approved for Allena Pharmaceuticals, Inc.	23-04-12	CI
Liquidation Plan and Disclosure Statement Filed by Allena Pharmaceuticals, Inc.	23-03-17	CI
North American Morning Briefing : Caution Continues to Dominate; Tesla Stock Extends Slide	22-12-28	DJ
North American Morning Briefing : Futures Rise -2-	22-12-21	DJ
North American Morning Briefing : Investors Wary -2-	22-12-14	DJ
North American Morning Briefing : Stocks to -2-	22-12-07	DJ
Motion for Asset Sale Approved for Allena Pharmaceuticals, Inc.	22-12-05	CI
North American Morning Briefing : Powell in Focus -2-	22-11-30	DJ
North American Morning Briefing : Stock Futures -2-	22-11-16	DJ
Bidding Procedure Approved for Allena Pharmaceuticals, Inc.	22-09-28	CI
Allena Pharmaceuticals, Inc.(NasdaqCM:ALNA) dropped from S&P TMI Index	22-09-09	CI
Allena Pharmaceuticals, Inc.(OTCPK:ALNA.Q) dropped from NASDAQ Composite Index	22-09-07	CI
Allena Pharmaceuticals, Inc. Enters into Settlement Agreement with Pontifax Medison Finance L.P. and Pontifax Medison Finance L.P	22-09-02	CI
Allena Pharmaceuticals, Inc. Terminates Employment of Richard D. Katz as Chief Financial Officer	22-09-02	CI
Allena Pharmaceuticals, Inc. Terminates Employment of Louis Brenner as Chief Executive Officer	22-09-02	CI
Allena Pharmaceuticals, Inc. Announces Management Changes	22-09-02	CI
Motion for Asset Sale Filed by Allena Pharmaceuticals, Inc.	22-09-02	CI
Allena Pharmaceuticals, Inc. Filed for Bankruptcy	22-09-02	CI
North American Morning Briefing : Retailers in -2-	22-08-16	DJ
Allena Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Allena Pharmaceuticals, Inc. Provides ALLN-346 Program Update	22-08-11	CI
Allena Pharmaceuticals Says Enrollment Complete in Two Cohorts of Gout, Chronic Kidney Disease Treatment Study	22-07-19	MT

Chart Allena Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Allena Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The Company is focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). The Company's lead product candidate, ALLN-346, is an orally administered, urate-degrading enzyme for patients with hyperuricemia and gout in the setting of advanced CKD. The Company is conducting two Phase IIa for ALLN-346. The Company's wholly owned subsidiaries include Allena Pharmaceuticals Security Corporation (Security Corporation) and Allena Pharmaceuticals Ireland Limited.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REGENERON PHARMACEUTICALS, INC.	+9.15%	106B
VERTEX PHARMACEUTICALS INCORPORATED	-1.08%	104B
ARGENX SE	+6.90%	23.25B
BIONTECH SE	-11.55%	22.5B
GENMAB A/S	-7.22%	18.7B
WUXI APPTEC CO., LTD.	-37.08%	17.95B
BEIGENE, LTD.	-9.91%	16.99B
NEUROCRINE BIOSCIENCES, INC.	+7.55%	14.26B
SAREPTA THERAPEUTICS, INC.	+40.04%	12.76B

Bio Therapeutic Drugs